Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Review, H1 2016', provides in depth analysis on Toll Like Receptor 4 (CD284 or TLR4) targeted pipeline therapeutics. 

The report provides comprehensive information on the Toll Like Receptor 4 (CD284 or TLR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Toll Like Receptor 4 (CD284 or TLR4) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (CD284 or TLR4) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Toll Like Receptor 4 (CD284 or TLR4) Overview 10
Therapeutics Development 11
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Stage of Development 11
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Therapy Area 12
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Indication 13
Toll Like Receptor 4 (CD284 or TLR4) - Pipeline Products Glance 16
Late Stage Products 16
Early Stage Products 17
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Companies 18
Toll Like Receptor 4 (CD284 or TLR4) - Products under Development by Universities/Institutes 23
Toll Like Receptor 4 (CD284 or TLR4) - Therapeutics Assessment 25
Assessment by Monotherapy/Combination Products 25
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Toll Like Receptor 4 (CD284 or TLR4) - Companies Involved in Therapeutics Development 32
Batu Biologics, Inc. 32
BioLineRx, Ltd. 33
Biomedica Management Corporation 34
Eisai Co., Ltd. 35
eTheRNA Immunotherapies NV 36
Formune S.L. 37
GlaxoSmithKline Plc 38
Harbor Therapeutics, Inc. 39
Immune Design Corp. 40
Immunovo BV 41
Kyorin Pharmaceutical Co., Ltd. 42
NovImmune SA 43
Reliance Life Sciences Pvt. Ltd. 44
TaiwanJ Pharmaceuticals Co., Ltd. 45
Vascular Biogenics Ltd. 46
Toll Like Receptor 4 (CD284 or TLR4) - Drug Profiles 47
ApTLR-4FT - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
BL-1110 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
C-34 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
CRX-526 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
DMT-210 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
EDA-GP120 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
EDA-HPVE7 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
EDA-NS3 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
EDA-TRP2 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
eritoran tetrasodium - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
G-100 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Glyco-23 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
GSK-1795091 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
HE-3286 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
hp-91 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
ibudilast - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
JKB-117 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
JKB-119 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
JKB-121 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
naltrexone hydrochloride - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
NI-0101 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
P-13 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
P-16 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
P-7 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
P-MAPA - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
PEPA-10 - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
RSCL-0520 - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
Small Molecules to Antagonize Toll-Like Receptor 4 for Oncology and Autoimmune Disorders - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
VB-201 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
VB-3323 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
VB-703 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Toll Like Receptor 4 (CD284 or TLR4) - Dormant Projects 100
Toll Like Receptor 4 (CD284 or TLR4) - Discontinued Products 104
Toll Like Receptor 4 (CD284 or TLR4) - Featured News & Press Releases 105
Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate G100 At ASCO 105
May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana 105
May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 106
Apr 21, 2016: Immune Design Announces Presentations on G-100 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 106
Apr 20, 2016: MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada 107
Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016 108
Mar 30, 2016: MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence 109
Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis 110
Mar 07, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis 111
Mar 06, 2016: MediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas 111
Feb 22, 2016: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology 68th Annual Meeting in Vancouver, Canada 112
Feb 11, 2016: MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas 113
Feb 09, 2016: Immune Design Announces Data From Phase 1 Clinical Trial of G100 113
Feb 07, 2016: MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas 113
Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova's MN-166 (ibudilast) for the Treatment of Krabbe Disease 114
Appendix 115
Methodology 115
Coverage 115
Secondary Research 115
Primary Research 115
Expert Panel Validation 115
Contact Us 115
Disclaimer 116

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Number of Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Development by Companies, H1 2016 (Contd..2) 21
Products under Development by Companies, H1 2016 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Products under Investigation by Universities/Institutes, H1 2016 24
Assessment by Monotherapy/Combination Products, H1 2016 25
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 29
Number of Products by Stage and Molecule Type, H1 2016 31
Pipeline by Batu Biologics, Inc., H1 2016 32
Pipeline by BioLineRx, Ltd., H1 2016 33
Pipeline by Biomedica Management Corporation, H1 2016 34
Pipeline by Eisai Co., Ltd., H1 2016 35
Pipeline by eTheRNA Immunotherapies NV, H1 2016 36
Pipeline by Formune S.L., H1 2016 37
Pipeline by GlaxoSmithKline Plc, H1 2016 38
Pipeline by Harbor Therapeutics, Inc., H1 2016 39
Pipeline by Immune Design Corp., H1 2016 40
Pipeline by Immunovo BV, H1 2016 41
Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 42
Pipeline by NovImmune SA, H1 2016 43
Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2016 44
Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H1 2016 45
Pipeline by Vascular Biogenics Ltd., H1 2016 46
Dormant Projects, H1 2016 100
Dormant Projects (Contd..1), H1 2016 101
Dormant Projects (Contd..2), H1 2016 102
Dormant Projects (Contd..3), H1 2016 103
Discontinued Products, H1 2016 104